BEATRICE: No Significant Improvement in Invasive DFS with Addition of Bevacizumab to Adjuvant Chemotherapy for Triple-Negative Early Breast Cancer

Capsule Summary - The BEATRICE study showed that despite promising results with bevacizumab in triple-negative metastatic breast cancer, its addition to adjuvant chemotherapy offered no benefit for triple-negative early breast cancer.
Source: Clinical Care Options Oncology - Breast Cancer - Category: Cancer & Oncology Source Type: research